Novel c-Jun N-Terminal Kinase (JNK) Inhibitors with an 11H-Indeno[1,2-b]quinoxalin-11-one Scaffold

Bibliografiske detaljer
Parent link:Molecules
Vol. 26, iss. 18.— 2021.— [5688, 18 p.]
Institution som forfatter: Национальный исследовательский Томский политехнический университет Инженерная школа новых производственных технологий Научно-образовательный центр Н. М. Кижнера
Andre forfattere: Lyakhov S. A. Sergey, Shchepyotkin I. A. Igor Aleksandrovich, Karpenko A. S. Alexander, Duma N. I. Nanna, Gaidarzhy N. M. Nadiya, Kirpotina L. N. Liliya Nikolaevna, Kovrizhina A. R. Anastasia Ruslanovna, Khlebnikov A. I. Andrey Ivanovich, Bagryanskaya I. Yu. Irina Yurjevna, Quinn M. T. Mark
Summary:Title screen
c-Jun N-terminal kinase (JNK) plays a central role in stress signaling pathways implicated in important pathological processes, including rheumatoid arthritis and ischemia-reperfusion injury. Therefore, inhibition of JNK is of interest for molecular targeted therapy to treat various diseases. We synthesized 13 derivatives of our reported JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime and evaluated their binding to the three JNK isoforms and their biological effects. Eight compounds exhibited submicromolar binding affinity for at least one JNK isoform. Most of these compounds also inhibited lipopolysaccharide (LPS)-induced nuclear factor-kB/activating protein 1 (NF-kB/AP-1) activation and interleukin-6 (IL-6) production in human monocytic THP1-Blue cells and human MonoMac-6 cells, respectively. Selected compounds (4f and 4m) also inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. We conclude that indenoquinoxaline-based oximes can serve as specific small-molecule modulators for mechanistic studies of JNKs, as well as potential leads for the development of anti-inflammatory drugs.
Sprog:engelsk
Udgivet: 2021
Fag:
Online adgang:https://doi.org/10.3390/molecules26185688
Format: Electronisk Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=666255

MARC

LEADER 00000naa0a2200000 4500
001 666255
005 20250214141048.0
035 |a (RuTPU)RU\TPU\network\37459 
035 |a RU\TPU\network\36205 
090 |a 666255 
100 |a 20211213d2021 k||y0rusy50 ba 
101 0 |a eng 
102 |a CH 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Novel c-Jun N-Terminal Kinase (JNK) Inhibitors with an 11H-Indeno[1,2-b]quinoxalin-11-one Scaffold  |f S. A. Lyakhov, I. A. Shchepyotkin, A. S. Karpenko [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 60 tit.] 
330 |a c-Jun N-terminal kinase (JNK) plays a central role in stress signaling pathways implicated in important pathological processes, including rheumatoid arthritis and ischemia-reperfusion injury. Therefore, inhibition of JNK is of interest for molecular targeted therapy to treat various diseases. We synthesized 13 derivatives of our reported JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime and evaluated their binding to the three JNK isoforms and their biological effects. Eight compounds exhibited submicromolar binding affinity for at least one JNK isoform. Most of these compounds also inhibited lipopolysaccharide (LPS)-induced nuclear factor-kB/activating protein 1 (NF-kB/AP-1) activation and interleukin-6 (IL-6) production in human monocytic THP1-Blue cells and human MonoMac-6 cells, respectively. Selected compounds (4f and 4m) also inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. We conclude that indenoquinoxaline-based oximes can serve as specific small-molecule modulators for mechanistic studies of JNKs, as well as potential leads for the development of anti-inflammatory drugs. 
461 |t Molecules 
463 |t Vol. 26, iss. 18  |v [5688, 18 p.]  |d 2021 
610 1 |a труды учёных ТПУ 
610 1 |a электронный ресурс 
610 1 |a c-Jun N-terminal kinase 
610 1 |a kinase inhibitor 
610 1 |a 11H-indeno[1,2-b]quinoxalin-11-one 
610 1 |a oxime 
610 1 |a interleukin-6 
610 1 |a nuclear factor-kB 
610 1 |a ингибиторы 
610 1 |a киназы 
610 1 |a терапия 
610 1 |a противовоспалительные препараты 
701 1 |a Lyakhov  |b S. A.  |g Sergey 
701 1 |a Shchepyotkin  |b I. A.  |g Igor Aleksandrovich 
701 1 |a Karpenko  |b A. S.  |g Alexander 
701 1 |a Duma  |b N. I.  |g Nanna 
701 1 |a Gaidarzhy  |b N. M.  |g Nadiya 
701 1 |a Kirpotina  |b L. N.  |g Liliya Nikolaevna 
701 1 |a Kovrizhina  |b A. R.  |c biotechnology specialist  |c Research Engineer of Tomsk Polytechnic University  |f 1995-  |g Anastasia Ruslanovna  |3 (RuTPU)RU\TPU\pers\46608 
701 1 |a Khlebnikov  |b A. I.  |c Chemist  |c Professor of Tomsk Polytechnic University  |f 1963-  |g Andrey Ivanovich  |3 (RuTPU)RU\TPU\pers\33927  |9 17500 
701 1 |a Bagryanskaya  |b I. Yu.  |g Irina Yurjevna 
701 1 |a Quinn  |b M. T.  |g Mark 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Инженерная школа новых производственных технологий  |b Научно-образовательный центр Н. М. Кижнера  |3 (RuTPU)RU\TPU\col\23556 
801 2 |a RU  |b 63413507  |c 20211213  |g RCR 
856 4 0 |u https://doi.org/10.3390/molecules26185688 
942 |c CF